IHE

iShares U.S. Pharmaceuticals ETF
*Unless otherwise stated, data provided by FactSet.

IHE Fund Description

IHE tracks a broad-based, cap-weighted index of US pharmaceutical companies.

IHE Factset Analytics Insight

IHE provides comprehensive but skewed coverage of pharmaceuticals, holding about 40 of the largest US pharmaceutical names, and capping large holdings in an industry where three players (J&J, Pfizer and Merck) take up more than 40% of the market cap. This heavily tilts IHE toward mid- and small-caps compared to our benchmark. While pharmaceuticals account for a hefty majority of IHE, the fund also holds positions in biotech. Its departures from neutral exposure seem to have resulted in a fund with greater volatility than the market it's trying to capture. IHE sees inconsistent trading volume, and retail investors should be wary of considerable spreads, though underlying liquidity is better for large investors. IHE charges a typical fee for its segment, and tracking is roughly in-line with that fee, if not a little better thanks to its securities lending program.

IHE MSCI ESG Analytics Insight

iShares U.S. Pharmaceuticals ETF has an MSCI ESG Fund Rating of BBB based on a score of 4.71 out of 10. The MSCI ESG Fund Rating measures the resiliency of portfolios to long-term risks and opportunities arising from environmental, social, and governance factors. ESG Fund Ratings range from best (AAA) to worst (CCC). Highly rated funds consist of companies that tend to show strong and/or improving management of financially relevant environmental, social and governance issues. These companies may be more resilient to disruptions arising from ESG events.

The fund’s Peer Rank reflects the ranking of a fund’s MSCI ESG Fund Quality Score against the scores of other funds within the same peer group, as defined by the Thomson Reuters Lipper Global Classification. iShares U.S. Pharmaceuticals ETF ranks in the 34th percentile within its peer group and in the 42nd percentile within the global universe of all funds covered by MSCI ESG Fund Ratings.

IHE Charts And Performance

Price Chart ($)
Total Return Chart (%)
  • 1 Month
  • 3 Months
  • YTD
  • 1 Year
  • 3 Years
  • 5 Years
  • Max
  • 1 Month
  • 3 Months
  • YTD
  • 1 Year
  • 3 Years
  • 5 Years
  • Max
Compare
Reset
Select ETFs to compare their performance:
PERFORMANCE [as of 04/02/20] 1 MONTH 3 MONTHS YTD 1 YEAR 3 YEARS 5 YEARS 10 YEARS
IHE -10.93% -16.48% -16.24% -11.81% -2.64% -3.41% 9.88%
IHE (NAV) -11.12% -16.58% -16.35% -11.94% -2.69% -3.43% 9.86%
DJ US Select / Pharmaceutical -11.08% -16.50% -16.27% -11.65% -2.47% -3.16% 9.86%
Thomson Reuters US Pharmaceuticals -- -- -- -- -- -- --
All returns over 1 year are annualized. All returns are total returns unless otherwise stated.

IHE Summary Data

Blackrock
iShares
05/01/06
Open-Ended Fund
0.42%
$265.75M
$2.74M
0.09%

IHE Portfolio Data

$150.50B
88.10
3.47
1.75%
03/25/20
46

IHE Portfolio Management

0.42%
-0.19%
-0.14%
-0.41%

IHE Tax Exposures

20.00% / 39.60%
--
Qualified dividends
No

IHE Fund Structure

Open-Ended Fund
No
Yes
72% / 29%
N/A
N/A
Low
Daily
Cboe Book Viewer
Top Of Book
Last 10 Trades
Bats BZX Real-time Quote -

IHE Factset Analytics Block Liquidity

As of 04/03/20
5
4
3
2
1

This measurement shows how easy it is to trade a $1 million USD block of IHE. IHE is rated a 5 out of 5.

IHE Tradability

18,901
$2.74M
16,581
$2.22M
0.09%
$0.13
-0.02%
0.92% / -0.86%
None
100.00%
50,000
0.33
0.00%
0.23%
323
$133.32
5

IHE Sector/Industry Breakdown


IHE
Segment Benchmark
76.33%
88.27%
9.95%
5.06%
7.15%
--
3.11%
0.60%
2.68%
--
0.48%
0.07%
0.30%
--

IHE Top 10 Holdings[View All]

Allergan plc 4.46%
Catalent Inc 4.32%
Mylan N.V. 4.27%
Pfizer Inc. 4.23%
74.1%

IHE Countries


IHE
Segment Benchmark
100.00%
100.00%

IHE Regions


IHE
Segment Benchmark
100.00%
100.00%

IHE Economic Development


IHE
Segment Benchmark
100.00%
100.00%

IHE Performance Statistics

0.93
1.01
0.96
1.05
0.49%
Thomson Reuters US Pharmaceuticals

IHE MSCI ESG Ratings

4.71 / 10
41.89
33.82
--
7.40%
26.88

IHE Benchmark Comparison Holdings

46
49
25
61.70%

IHE Benchmark Comparison Summary


IHE
Segment Benchmark
46
49
$150.50B
$191.25B
88.10
23.44
3.47
4.83
1.67%
2.64%
High
High

IHE Benchmark Comparison Market Cap Size


IHE
Segment Benchmark
64.50%
95.54%
25.07%
3.26%
9.11%
1.06%
1.33%
0.14%